20 Feb2020
EnClear Therapies Announces $10M Series A Financing
– Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors —
— Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital, and Dolby Ventures —
CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today announced a $10 million Series A financing led by 20/20 HealthCare Partners (“20/20 HCP”), and joined by Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures.
READ FULL ARTICLE